Company Encyclopedia
View More
name
SINOPHARM
01099.HK
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and healthcare products, and medical devices in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices Distribution, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics.
167.48 B
01099.HKMarket value -Rank by Market Cap -/-

Financial Score

30/12/2025 Update
D
Health Care DistributorsIndustry
Industry Ranking17/21
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE0.00%D
    • Profit Margin1.23%C
    • Gross Margin7.21%E
  • Growth ScoreD
    • Revenue YoY-4.28%D
    • Net Profit YoY-14.94%D
    • Total Assets YoY0.00%C
    • Net Assets YoY0.00%C
  • Cash ScoreB
    • Cash Flow Margin8103.66%A
    • OCF YoY-4.28%D
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreD
    • Gearing Ratio68.41%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sinopharm Group Files Director List with HKEX

    Sinopharm Group Co. Ltd. has filed an updated list of directors with the Hong Kong Stock Exchange, detailing their roles and committee memberships. The board includes Non-Executive, Executive, and Independent Non-Executive Directors, with Jin Bin as Chairman. The filing reflects a broad distribution of responsibilities across governance, strategy, compliance, remuneration, and nomination functions. This information was published by Sinopharm Group via the Hong Kong Stock Exchange's Issuer Information Service.

    Reuters·
    HK
    01099
    +0.05%
    Reuters·
    HK
    01099
    +0.05%

    Sinopharm Group (SEHK:1099): Valuation Check After Renewing Shanghai Henlius Distribution Partnership

    Sinopharm Group's renewed distribution partnership with Shanghai Henlius Biotech extends their collaboration until 2028. Despite a modest recent share price increase, Sinopharm's long-term returns remain strong. The company's current price-to-earnings ratio of 8.1x suggests undervaluation compared to industry averages. However, a DCF model indicates a fair value of HK$15.36, suggesting potential overvaluation. Risks include policy changes and slower procurement growth. Investors are encouraged to explore further investment opportunities and assess potential mispricing in the market.

    Simplywall·
    HK
    01099
    +0.05%
    Simplywall·
    HK
    01099
    +0.05%

    Sinopharm Group Co. Ltd. Announces Date for Extraordinary General Meeting

    Sinopharm Group Co. Ltd. will hold an extraordinary general meeting on December 19, 2025, in Shanghai, China. Shareholders will vote on appointing Mr. Jin Bin and Ms. Li Ying as non-executive Directors of the Board, with authorization for the Board to determine their remuneration and service contracts. This announcement was published by Sinopharm Group via the Hong Kong Stock Exchange's Issuer Information Service.

    Reuters·
    HK
    01099
    +0.05%
    Reuters·
    HK
    01099
    +0.05%

    Shanghai Henlius Biotech Renews Distribution Agreement with Sinopharm

    Shanghai Henlius Biotech Inc. has renewed its distribution agreement with Sinopharm Group, signing a new framework on December 3, 2025. This extends their partnership, with transactions conducted in the ordinary course of business. An Independent Board Committee will advise shareholders on the agreement's fairness. The news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    HK
    01099
    +0.05%
    HK
    02696
    +0.09%
    Reuters·
    HK
    01099
    +0.05%
    HK
    02696
    +0.09%

    SINOPHARM appoints chairman

    SINOPHARM announced that due to work arrangements, Zhao Bingxiang has resigned from his positions as non-executive director and chairman of the board on November 28. The board has resolved to elect Jin Bin as the chairman and authorized representative, and on the same day appointed Jin Bin and Li Ying as non-executive directors

    AASTOCKS·
    HK
    01099
    +0.05%
    AASTOCKS·
    HK
    01099
    +0.05%
    © 2025 Longbridge｜Disclaimer